Phase I Study of Temozolomide and Irinotecan for Recurrent Malignant Gliomas in Patients Receiving Enzyme-Inducing Antiepileptic Drugs: A North American BrainTumor Consortium Study

PURPOSE: To determine the maximum tolerated dose of irinotecan when administrated with temozolomide every 28 days, in patients with recurrent malignant glioma who were also receiving CYP450 enzyme-inducing antiepileptic drugs (EIAED), and to characterize the pharmacokinetics of irinotecan and its me...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Clin Cancer Res
Prif Awduron: Loghin, Monica E., Prados, Michael D., Wen, Patrick, Junck, Larry, Lieberman, Frank, Fine, Howard, Fink, Karen L., Metha, Minesh, Kuhn, John, Lamborn, Kathleen, Chang, Susan M., Cloughesy, Timothy, DeAngelis, Lisa M., Robins, Ian H., Aldape, Kenneth D., AlfredYung, W.K.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2007
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4802002/
https://ncbi.nlm.nih.gov/pubmed/18056194
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-07-0874
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg